• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

U.S. Surgical allowed to market ABBI

Article

The Food and Drug Administration has notified U.S. Surgical thatit will allow the Norwalk, CT, company to continue to market itsAdvanced Breast Biopsy Instrumentation (ABBI) device under theproduct's existing 510(k) application. The FDA issued a

The Food and Drug Administration has notified U.S. Surgical that

it will allow the Norwalk, CT, company to continue to market its

Advanced Breast Biopsy Instrumentation (ABBI) device under the

product's existing 510(k) application. The FDA issued a warning

letter to U.S. Surgical last month, claiming that ABBI's 510(k)

application did not include an indication for breast biopsy (SCAN

6/19/96). U.S. Surgical denied the FDA's claims. The two sides

are in negotiations to resolve any remaining issues related to

ABBI advertising and labeling, according to the company.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.